Wilbanks Smith & Thomas Asset Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $2.74M | Sell |
98,677
-1,446
| -1% | -$40.1K | 0.08% | 147 |
|
|
2023
Q4 | $2.88M | Sell |
100,123
-53,218
| -35% | -$1.61M | 0.09% | 136 |
|
|
2023
Q3 | $5.09M | Sell |
153,341
-20,011
| -12% | -$708K | 0.18% | 99 |
|
|
2023
Q2 | $6.36M | Sell |
173,352
-18,902
| -10% | -$736K | 0.21% | 97 |
|
|
2023
Q1 | $7.84M | Buy |
192,254
+2,951
| +2% | +$127K | 0.27% | 80 |
|
|
2022
Q4 | $9.7M | Buy |
189,303
+1,517
| +0.8% | +$72.7K | 0.37% | 68 |
|
|
2022
Q3 | $8.22M | Buy |
187,786
+1,748
| +0.9% | +$84.9K | 0.35% | 74 |
|
|
2022
Q2 | $9.75M | Buy |
186,038
+10,032
| +6% | +$511K | 0.41% | 63 |
|
|
2022
Q1 | $8.68M | Buy |
176,006
+6,396
| +4% | +$332K | 0.35% | 70 |
|
|
2021
Q4 | $10M | Buy |
169,610
+6,951
| +4% | +$344K | 0.35% | 70 |
|
|
2021
Q3 | $7M | Buy |
162,659
+10,744
| +7% | +$476K | 0.27% | 90 |
|
|
2021
Q2 | $5.95M | Buy |
151,915
+3,544
| +2% | +$138K | 0.23% | 97 |
|
|
2021
Q1 | $5.38M | Buy |
148,371
+4,705
| +3% | +$167K | 0.23% | 94 |
|
|
2020
Q4 | $5.29M | Sell |
143,666
-6,839
| -5% | -$251K | 0.25% | 89 |
|
|
2020
Q3 | $5.24M | Sell |
150,505
-627
| -0.4% | -$22K | 0.28% | 81 |
|
|
2020
Q2 | $4.69M | Buy |
151,132
+2,055
| +1% | +$69.8K | 0.28% | 80 |
|
|
2020
Q1 | $4.62M | Buy |
149,077
+25,384
| +21% | +$865K | 0.34% | 62 |
|
|
2019
Q4 | $4.6M | Sell |
123,693
-10,751
| -8% | -$383K | 0.27% | 79 |
|
|
2019
Q3 | $4.58M | Sell |
134,444
-1,543
| -1% | -$56.1K | 0.29% | 78 |
|
|
2019
Q2 | $5.59M | Sell |
135,987
-780
| -0.6% | -$31K | 0.36% | 63 |
|
|
2019
Q1 | $5.51M | Buy |
136,767
+4,479
| +3% | +$179K | 0.36% | 64 |
|
|
2018
Q4 | $5.48M | Sell |
132,288
-8,052
| -6% | -$334K | 0.38% | 49 |
|
|
2018
Q3 | $5.87M | Sell |
140,340
-14,306
| -9% | -$551K | 0.36% | 55 |
|
|
2018
Q2 | $5.32M | Sell |
154,646
-1,207
| -0.8% | -$41.2K | 0.43% | 49 |
|
|
2018
Q1 | $5.25M | Buy |
155,853
+3,092
| +2% | +$106K | 0.42% | 49 |
|
|
2017
Q4 | $5.25M | Buy |
152,761
+6,334
| +4% | +$216K | 0.42% | 47 |
|
|
2017
Q3 | $4.96M | Buy |
146,427
+3,143
| +2% | +$101K | 0.42% | 48 |
|
|
2017
Q2 | $4.57M | Sell |
143,284
-224
| -0.2% | -$7.06K | 0.4% | 50 |
|
|
2017
Q1 | $4.66M | Buy |
143,508
+1,017
| +0.7% | +$32.1K | 0.4% | 49 |
|
|
2016
Q4 | $4.39M | Buy |
142,491
+35,698
| +33% | +$1.09M | 0.39% | 46 |
|
|
2016
Q3 | $3.43M | Sell |
106,793
-21,452
| -17% | -$717K | 0.32% | 56 |
|
|
2016
Q2 | $4.28M | Sell |
128,245
-1,072
| -0.8% | -$34.2K | 0.45% | 42 |
|
|
2016
Q1 | $3.64M | Buy |
129,317
+4,270
| +3% | +$122K | 0.44% | 43 |
|
|
2015
Q4 | $3.83M | Buy |
125,047
+22,625
| +22% | +$712K | 0.38% | 42 |
|
|
2015
Q3 | $3.05M | Sell |
102,422
-23,200
| -18% | -$744K | 0.43% | 45 |
|
|
2015
Q2 | $4M | Sell |
125,622
-21
| -0% | -$684 | 0.39% | 41 |
|
|
2015
Q1 | $4.15M | Sell |
125,643
-677
| -0.5% | -$21.5K | 0.41% | 40 |
|
|
2014
Q4 | $3.73M | Buy |
126,320
+3,555
| +3% | +$102K | 0.38% | 43 |
|
|
2014
Q3 | $3.44M | Buy |
122,765
+3,488
| +3% | +$97.9K | 0.38% | 46 |
|
|
2014
Q2 | $3.36M | Sell |
119,277
-2,291
| -2% | -$65.3K | 0.36% | 47 |
|
|
2014
Q1 | $3.71M | Buy |
121,568
+1,115
| +0.9% | +$33.2K | 0.42% | 41 |
|
|
2013
Q4 | $3.5M | Sell |
120,453
-16,319
| -12% | -$475K | 0.42% | 42 |
|
|
2013
Q3 | $3.73M | Buy |
136,772
+5,310
| +4% | +$144K | 0.5% | 38 |
|
|
2013
Q2 | $3.49M | Buy |
+131,462
| New | +$3.63M | 0.54% | 39 |
|
Other funds holding PFE
Wilbanks Smith & Thomas Asset Management's PFE Position: Q1 2024 in Review
Wilbanks Smith & Thomas Asset Management reduced its Pfizer (PFE) stake by 1.4% in Q1 2024, selling an estimated $40.1K and leaving 98,677 shares worth $2.74M. The position accounts for 0.08% of the portfolio, ranked #147.
Wilbanks Smith & Thomas Asset Management first reported a position in PFE in Q2 2013 and has held it in 44 quarters since. The position peaked at $10M in Q4 2021. 2,875 funds tracked by Wall St. Rank hold PFE as of Q1 2024.
- Wilbanks Smith & Thomas Asset Management held 98,677 shares of Pfizer worth $2.74M as of Q1 2024.
- Wilbanks Smith & Thomas Asset Management sold 1,446 Pfizer shares in Q1 2024, an estimated $40.1K.
- Pfizer made up 0.08% of Wilbanks Smith & Thomas Asset Management's portfolio in Q1 2024, its #147 holding.
- Wilbanks Smith & Thomas Asset Management first reported a position in Pfizer in Q2 2013 and has held it in 44 quarters since.
- Wilbanks Smith & Thomas Asset Management's Pfizer position peaked at $10M in Q4 2021.
- 2,875 funds tracked by Wall St. Rank held Pfizer as of Q1 2024.
Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q1 2024, filed 7 May 2024.